Plant-Derived Bioactive Compounds in Inflammation-Related Cancers: Mechanisms and Therapeutic Potential
Plants · 12.02.2026 · 15 (4) · 575
DOI: 10.3390/plants15040575 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Plants, online erschienen am 12.02.2026. Verfasst von Mingzhu Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic inflammation is a well-established driving force in tumor initiation and progression, accounting for a substantial proportion of inflammation-associated malignancies. Persistent inflammatory stimulation creates a pathological microenvironment characterized by sustained inflammatory signaling, oxidative stress, immune dysregulation, and epigenetic reprogramming, which collectively promote genomic instability, malignant transformation, and tumor progression. Understanding the biological basis of inflammation–cancer transformation is therefore essential for the development of effective preventive and therapeutic strategies. Plant-derived bioactive compounds have attracted increasing attention as promising modulators of inflammation-driven carcinogenesis due to their structural diversity, multi-target regulatory capacity, and relatively low toxicity. Specifically, this review focuses on four major classes of these compounds: flavonoids, alkaloids, terpenoids, and curcuminoids. Accumulating evidence demonstrates that these compounds can effectively interrupt the inflammation–cancer continuum by simultaneously targeting multiple pathogenic processes rather than single molecular pathways. In particular, these plant-derived agents suppress inflammation-driven signaling cascades, including NF-κB, MAPK, and JAK/STAT pathways; attenuate oxidative stress and inflammation-induced DNA damage; reprogram the immune microenvironment to restore anti-tumor immunity; and modulate epigenetic and transcriptional programs that stabilize pro-tumorigenic phenotypes. Accordingly, this review synthesizes the shared pathological drivers of inflammation–cancer transformation and summarizes how plant-derived compounds collectively target these mechanisms to interrupt disease progression. In addition, emerging translational strategies, including combination therapy and nanocarrier-based delivery systems, are discussed to highlight the clinical potential of plant-derived interventions. Collectively, this review offers an integrated mechanistic framework for understanding and exploiting plant-derived bioactive compounds in the prevention and treatment of inflammation-related cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China.
ORCID-Profile: Jiao Feng, Xinbing Sui
Zitieren
APA
Song, M., Zhu, X., Zhao, X., Feng, J., & Sui, X. (2026). Plant-Derived Bioactive Compounds in Inflammation-Related Cancers: Mechanisms and Therapeutic Potential. Plants, 15(4), 575. https://doi.org/10.3390/plants15040575
Vancouver
Song M, Zhu X, Zhao X, Feng J, Sui X. Plant-Derived Bioactive Compounds in Inflammation-Related Cancers: Mechanisms and Therapeutic Potential. Plants. 2026;15(4):575. doi:10.3390/plants15040575
BibTeX
@article{Song2026,
author = {Song, Mingzhu and Zhu, Xiaolong and Zhao, Xiaohong and Feng, Jiao and Sui, Xinbing},
title = {Plant-Derived Bioactive Compounds in Inflammation-Related Cancers: Mechanisms and Therapeutic Potential},
journal = {Plants},
year = {2026},
volume = {15},
number = {4},
pages = {575},
doi = {10.3390/plants15040575}
}
EUVIMED